John Krystal, MD
John H. Krystal, MD
Robert L. McNeil, Jr., Professor of Translational Research
Chair, Department of Psychiatry
Yale University School of Medicine
Chief of Psychiatry, Yale-New Haven Hospital
Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research and Chair of the Department of Psychiatry of the Yale University School of Medicine and Chief of Psychiatry at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Department of Psychiatry Residency Training Program. He has published over 350 papers and chapters on the neurobiology and treatment of alcoholism, schizophrenia, post-traumatic stress disorder, and depression. His research program unites psychopharmacology, neuroimaging, and molecular genetics. His work on brain glutamate systems contributed to the identification of novel treatment mechanisms for alcoholism, depression, and schizophrenia, that are now in development.
He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism, VA Alcohol Research Center, and Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal received the Joel Elkes Award of the American College of Neuropsychopharmacology (ACNP), the Han Jönas Weitbrecht Scientific Award from Bayer, the APIRE/Kempf Fund Award of the American Psychiatric Association, the Anna-Monika Foundation Prize, and other awards. He was Chairman of the NIMH Board of Scientific Counselors (2004-2007) and he currently serves on the NIAAA National Alcohol Advisory Council and the Department of Defense Psychological Health Advisory Board. He has served in leadership roles in several professional societies. He currently serves on the boards of directors of the ACNP and the Society of Biological Psychiatry. Since 2006, he has edited one of the leading journals in psychiatry and neuroscience, Biological Psychiatry
Talk Title: Targeting glutamatergic neuroplasticity to enhance cognitive/behavioral therapy for anxiety disorders.
Reading List – Click here for PDF set one, click here for PDF set two, click here for PDF set three
- Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG,
Eisenmenger K, Krystal JH, Pollack MH. Efficacy of D-Cycloserine for Enhancing
Response to Cognitive-Behavior Therapy for Panic Disorder.Biol Psychiatry epub ahead of print 2009 - Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman
RE, D’Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety
disorders, mood disorders, and schizophrenia. Drug Discov Today.
Epub 2009 - Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the
facilitation of fear extinction and exposure therapy. Biol Psychiatry 15;63(12):1118-26, 2008 - Neumeister A, Carson R, Henry S, Planeta-Wilson B, Binneman B, Maguire RP,
Luckenbaugh DA, D’Souza C, Krystal JH, Frost JJ. Cerebral metabolic effects of
intravenous glycine in healthy human subjects. J Clin Psychopharmacol (6):595-9, 2006 - D’Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R,
Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral
D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol
Psychiatry 47(5):450-62, 2000 - D’Souza DC, Charney DS, Krystal JH: Glycine site agonists of the NMDA receptor: a review. CNS Drug Reviews 1:227-260, 1995
.